These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17266573)

  • 1. Towards better brain management: nootropics.
    Malik R; Sangwan A; Saihgal R; Jindal DP; Piplani P
    Curr Med Chem; 2007; 14(2):123-31. PubMed ID: 17266573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders.
    Morè L; Lauterborn JC; Papaleo F; Brambilla R
    Neurosci Biobehav Rev; 2020 Mar; 110():28-45. PubMed ID: 30981451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In search of the mechanism of action of the nootropics: new insights and potential clinical implications.
    Mondadori C
    Life Sci; 1994; 55(25-26):2171-8. PubMed ID: 7997076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 41(4):961-1019. PubMed ID: 24898652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.
    Malík M; Tlustoš P
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nootropics: preclinical results in the light of clinical effects; comparison with tacrine.
    Mondadori C
    Crit Rev Neurobiol; 1996; 10(3-4):357-70. PubMed ID: 8978986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.
    Gualtieri F; Manetti D; Romanelli MN; Ghelardini C
    Curr Pharm Des; 2002; 8(2):125-38. PubMed ID: 11812254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2013; 34(1):1-114. PubMed ID: 23186990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2013; 33(3):547-658. PubMed ID: 23042218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising therapeutics with natural bioactive compounds for improving learning and memory--a review of randomized trials.
    Kumar H; More SV; Han SD; Choi JY; Choi DK
    Molecules; 2012 Sep; 17(9):10503-39. PubMed ID: 22945029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibitors for cognitive enhancement.
    Rose GM; Hopper A; De Vivo M; Tehim A
    Curr Pharm Des; 2005; 11(26):3329-34. PubMed ID: 16250839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical evaluation of cognition enhancing drugs.
    Schindler U
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S99-115. PubMed ID: 2694232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experts urge smart thinking on cognitive enhancers.
    Morris K
    Lancet Neurol; 2008 Jun; 7(6):476-7. PubMed ID: 18485312
    [No Abstract]   [Full Text] [Related]  

  • 15. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics.
    Marwaha A; Goel RK; Mahajan MP
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5251-5. PubMed ID: 17643300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling pathways relevant to cognition-enhancing drug targets.
    Ménard C; Gaudreau P; Quirion R
    Handb Exp Pharmacol; 2015; 228():59-98. PubMed ID: 25977080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognition enhancers between treating and doping the mind.
    Lanni C; Lenzken SC; Pascale A; Del Vecchio I; Racchi M; Pistoia F; Govoni S
    Pharmacol Res; 2008 Mar; 57(3):196-213. PubMed ID: 18353672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.